Clinical Characteristics of Primary Non-PSMA-Expressing Prostate Cancer on preoperative PSMA PET/CT.
Hans VeermanMaarten DonswijkElise BekersJudith Olde HeuvelYves J L BodarThierry N BoellaardMaurits L van MontfoortR Jeroen A van MoorselaarDaniela E Oprea-LagerPim J Leeuwen vanAndré N VisHendrik van der PoelPublished in: BJU international (2021)
Prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) is a modern imaging tool used in the diagnosis of prostate cancer (PCa). Approximately 10% of patients who underwent PSMA PET/CT have a biopsy-proven, primary PCa without PSMA expression on PET/CT (non-PSMAPET -expressing PCa), according to a recent systematic review[1]. However, the definition of non-PSMAPET -expression in these studies was poorly defined and no immunohistochemical studies for confirmation of PSMA protein expression were performed. The aim of this retrospective study was to report the prevalence, characteristics, and immunohistochemical assessment of non-PSMAPET -expressing hormone-sensitive PCa in a cohort of 362 patients who underwent PSMA PET/CT and robot-assisted radical prostatectomy (RARP).
Keyphrases
- pet ct
- positron emission tomography
- prostate cancer
- radical prostatectomy
- computed tomography
- end stage renal disease
- systematic review
- robot assisted
- ejection fraction
- newly diagnosed
- peritoneal dialysis
- prognostic factors
- randomized controlled trial
- risk factors
- pet imaging
- minimally invasive
- magnetic resonance
- ultrasound guided